These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35647911)

  • 21. 3rd Sandoz Symposium on the Treatment of Parkinson's Disease. Tokyo, Japan, October 7-8, 1994. Proceedings.
    Eur Neurol; 1996; 36 Suppl 1():1-62. PubMed ID: 8964280
    [No Abstract]   [Full Text] [Related]  

  • 22. [Parkinson disease. Etiology, physiopathology, diagnosis, development, treatment].
    Fénelon G
    Rev Prat; 1996 Nov; 46(17):2137-44. PubMed ID: 8978170
    [No Abstract]   [Full Text] [Related]  

  • 23. Symposium on a Long Time Clinical Care of Parkinson's Disease. Tokyo, April 12, 1986. Proceedings.
    Eur Neurol; 1987; 26 Suppl 1():1-56. PubMed ID: 3495437
    [No Abstract]   [Full Text] [Related]  

  • 24. Nocturia and overnight polysomnography in Parkinson disease.
    Vaughan CP; Juncos JL; Trotti LM; Johnson TM; Bliwise DL
    Neurourol Urodyn; 2013 Nov; 32(8):1080-5. PubMed ID: 23359220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mental symptoms in parkinsonism following benzhexol hydrochloride therapy.
    PORTEOUS HB; ROSS DN
    Br Med J; 1956 Jul; 2(4985):138-40. PubMed ID: 13329405
    [No Abstract]   [Full Text] [Related]  

  • 26. 4th Symposium on a Long Term Clinical Care of Parkinson's Disease. Tokyo, April 22, 1989. Proceedings.
    Eur Neurol; 1990; 30 Suppl 1():1-40. PubMed ID: 2311635
    [No Abstract]   [Full Text] [Related]  

  • 27. Translational research in neurology and neuroscience 2011: movement disorders.
    Klein C; Krainc D; Schlossmacher MG; Lang AE
    Arch Neurol; 2011 Jun; 68(6):709-16. PubMed ID: 21320985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More than just a movement disorder: Why cognitive training is needed in Parkinson disease.
    Ventura MI; Edwards JD; Barnes DE
    Neurology; 2015 Nov; 85(21):1828-9. PubMed ID: 26519546
    [No Abstract]   [Full Text] [Related]  

  • 29. Diagnosis and Treatment of Parkinson Disease: A Review.
    Armstrong MJ; Okun MS
    JAMA; 2020 Feb; 323(6):548-560. PubMed ID: 32044947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient Views on Telemedicine for Parkinson Disease.
    Spear KL; Auinger P; Simone R; Dorsey ER; Francis J
    J Parkinsons Dis; 2019; 9(2):401-404. PubMed ID: 31127732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical aspects and treatment of parkinsonism. International Symposium. Moscow, October 21-23, 1991.
    Neurology; 1993 Feb; 43(2 Suppl 1):1-48. PubMed ID: 8094237
    [No Abstract]   [Full Text] [Related]  

  • 32. 17th Symposium on the Treatment of Parkinson's Disease. September 27, 2008, Tokyo. Foreword.
    Kuzuhara S; Takahashi R
    J Neurol; 2009 Aug; 256 Suppl 3():269. PubMed ID: 19711115
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-Parkinson drugs and their relationship to glaucoma.
    EDWARDS CE; O'DOHERTY DS
    Bull Georgetown Univ Med Cent; 1958 Sep; 12(1):15-6. PubMed ID: 13573001
    [No Abstract]   [Full Text] [Related]  

  • 34. Kick and rush: paradoxical kinesia in Parkinson disease.
    Asmus F; Huber H; Gasser T; Schöls L
    Neurology; 2008 Aug; 71(9):695. PubMed ID: 18725599
    [No Abstract]   [Full Text] [Related]  

  • 35. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II.
    Litvan I; Chesselet MF; Gasser T; Di Monte DA; Parker D; Hagg T; Hardy J; Jenner P; Myers RH; Price D; Hallett M; Langston WJ; Lang AE; Halliday G; Rocca W; Duyckaerts C; Dickson DW; Ben-Shlomo Y; Goetz CG; Melamed E
    J Neuropathol Exp Neurol; 2007 May; 66(5):329-36. PubMed ID: 17483689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based medicine (EBM) applied to Parkinson's disease treatment.
    Sampaio C; Ferreira JJ; Costa J
    Parkinsonism Relat Disord; 2002 Oct; 9(1):7-13. PubMed ID: 12217617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Movement disorders in Parkinson's disease: pathophysiology and therapeutic implications].
    Pascual-Leone A; Valls-Solé J; Hernández S; Hallett M
    Neurologia; 1994; 9(7):287-94. PubMed ID: 7946424
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacologic agents used in the treatment of movement disorders.
    CORBIN KB
    Res Publ Assoc Res Nerv Ment Dis; 1959; 37():86-103. PubMed ID: 13646043
    [No Abstract]   [Full Text] [Related]  

  • 39. Risky behaviors and Parkinson disease: A mendelian randomization study.
    Grover S; Lill CM; Kasten M; Klein C; Del Greco M F; König IR
    Neurology; 2019 Oct; 93(15):e1412-e1424. PubMed ID: 31527283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symposium on Parkinson's disease. Introduction.
    Dejong JD
    Prim Care; 1977 Sep; 4(3):391-401. PubMed ID: 264218
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.